Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Editas Medicine, Inc.

EDIT ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$2.74

▲ +1.48%

Market Cap $420.81M · Vol 431.19K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$420.81M

Small Cap

Div Yield

N/A

EPS Growth

+56.76%

YoY

RSI (14)

41.77

Momentum

Beta

1.99

vs Market

52W High

$4.53

39.51% below

52W Low

$1.66

65.06% above

Volume

431.19K

Avg 651.71K

P/B

7.35

Price-to-book

ROE

-198.14%

Return on equity

Free Float

99.82%

Public shares

Shariah Compliance8 STANDARDS

✗ Editas Medicine, Inc. (EDIT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EDIT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-15.17%

-2.84%

+9.60%

+12.30%

YTD

+33.66%

+1.86%

-67.34%

-95.49%

Financials & Valuation

TTM · Annual

Total Revenue	$40.52M
Net Income	$-160,060,000.00
Revenue Growth (YoY)	+232.31%
Gross Margin	100.00%
Operating Margin	-245.15%
Net Profit Margin	-395.01%
ROE	-198.14%
ROA · ROIC	-60.61% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	4.49
P/B	7.35
P/FCF	N/A
EPS Growth	+56.76%
Outstanding Shares	153.58M

Technical Indicators

50-Day SMA	$2.97
200-Day SMA	$2.62
RSI (14)	41.77
Beta	1.99
52-Week High	$4.53
52-Week Low	$1.66

Volume Today	431.19K
Avg Daily Volume (30D)	651.71K
Relative Volume	0.66x
Volatility (10D)	63.14
Volatility (30D)	76.12
Free Float	99.82%

Analyst Consensus

BUY

Current Price $2.74

Mean Target $6.14

52W Low$1.66 52W High$4.53

Current

Target

$1.66 $4.53

Current Analyst target

+124.19% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG005MX5H08

ISINUS28106W1036

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.56% ONC BeOne Medicines AG +2.11% 068270.KS Celltrion, Inc. +0.34% ABVX Abivax SA -4.27% ABVX.PA Abivax SA -1.63%

Company Profile

Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.